<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01486745</url>
  </required_header>
  <id_info>
    <org_study_id>MTI-2008</org_study_id>
    <secondary_id>514</secondary_id>
    <nct_id>NCT01486745</nct_id>
  </id_info>
  <brief_title>Urine Metabolomics and Colorectal Cancer Screening</brief_title>
  <official_title>Is There a Role for Using NMR Urine Metabolomics as a New Method of Screening for Colorectal Cancer?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-centered study to assess whether urine metabolomics can play a&#xD;
      role in the screening of colorectal cancer (CRC). Urine samples will be collected from 1000&#xD;
      patients going through an established CRC screening program, and from a further 500 patients&#xD;
      who already have a diagnosis of CRC. Using nuclear magnetic resonance (NMR) spectroscopy, the&#xD;
      1H NMR spectrum of urine samples will be analyzed for specific metabolites, and establish the&#xD;
      metabolomic signature of colorectal cancer. The results from metabolomic urinalysis of this&#xD;
      screening cohort will be compared with results from colonoscopy, histological descriptions,&#xD;
      fecal occult blood testing (FOBT), and fecal immune testing (FIT) to assess the accuracy of&#xD;
      urine metabolomics in identifying patients with polyps and malignancies. The urine&#xD;
      metabolomic results from the colorectal cancer group will be correlated with operative,&#xD;
      histological and clinical staging to define the role of urine metabolomics in assessing&#xD;
      colorectal cancer type, location and stage. Additionally approximately 300 urine samples from&#xD;
      breast cancer patients and 300 from prostate cancer patients will be collected to validate&#xD;
      that the colorectal cancer signature is unique.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2008</start_date>
  <completion_date type="Actual">July 31, 2017</completion_date>
  <primary_completion_date type="Actual">July 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">2175</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Colorectal Polyps</condition>
  <arm_group>
    <arm_group_label>Normal colonoscopy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Colonic polyps</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Colorectal cancer patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Breast &amp; Prostate Cancer patients</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects undergoing colorectal cancer screening Patients with diagnosis of colorectal&#xD;
        cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For Screening group (normal colonoscopy &amp; colonic polyps):&#xD;
&#xD;
          -  asymptomatic, 50-75 year old, without personal or family history of CRC/polyps&#xD;
&#xD;
          -  asymptomatic, 40-75 year old, known personal or first-degree family history of either&#xD;
             CRC or polyps&#xD;
&#xD;
        For Cancer group:&#xD;
&#xD;
          -  any patient with diagnosis of colorectal cancer&#xD;
&#xD;
          -  any patient with diagnosis of prostate cancer&#xD;
&#xD;
          -  any patient with diagnosis of breast cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For screening group:&#xD;
&#xD;
          -  hematochezia&#xD;
&#xD;
          -  inflammatory bowel disease&#xD;
&#xD;
          -  on anticoagulation for reasons other than atrial fibrillation&#xD;
&#xD;
          -  significant co-morbidities&#xD;
&#xD;
        For Cancer group:&#xD;
&#xD;
          -  already had neoadjuvant treatment at time of urine collection&#xD;
&#xD;
          -  no invasive cancer at time of urine collection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haili Wang, MD FRCS(C)</last_name>
    <role>Study Director</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 3, 2011</study_first_submitted>
  <study_first_submitted_qc>December 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2011</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

